Abstract:In this study, we described a series of 2,8-diazaspiro[4.5]decan-1-one derivatives as selective TYK2/JAK1 inhibitors. Systematic exploration of the structure–activity relationship through the introduction of spirocyclic scaffolds based on the reported selective TYK2 inhibitor 14l led to the discovery of the superior derivative compound 48. Compound 48 showed excellent potency on TYK2/JAK1 kinases with IC50 values of 6 and 37 nM, respectively, and exhibited more than 23-fold selectivity for JAK2. Compound 48 also demonstrated excellent metabolic stability and more potent anti-inflammatory efficacy than tofacitinib in acute ulcerative colitis models. Moreover, the excellent anti-inflammatory effect of compound 48 was mediated by regulating the expression of related TYK2/JAK1-regulated genes, as well as the formation of Th1, Th2, and Th17 cells. Taken together, these findings suggest that compound 48 is a selective dual TYK2/JAK inhibitor, deserving to be developed as a clinical candidate.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01137.Listing the metabolic stability of the preferred compounds (Table S1); listing binding affinities of 48 with 110 protein kinases (Table S2); listing the disease activity index (DAI) scoring system (Table S3); listing the IL-6, TNF-α, and IL-10 concentrations in Serum of UC Mice (Table S4); listing the primer sequence (Table S5); listing the docking results of compounds 48, 8, and 11 (Figure S1); listing the inhibition patterns of compound 48 and different drugs on different phosphorylated STATs (Figure S2); listing the relative gray quantitative analysis of p-STATs after treatment of 48 (Figure S3); listing the inhibitory effect of compound 48 on the p-STAT3 after cytokine stimulation (Figure S4); listing the in vivo assays of tissue distribution mice (Figure S5); listing the HE staining of heart, liver, spleen, lungs, and kidneys (Figure S6); listing the detection of levels of proteins in the colon tissue of UC mice by western blot (Figure S7); listing the effect of 48 on the expression of Th1, Th2, and Th17 cells (Figure S8); listing the HPLC of compounds 8, 33, 41, 48, and 49, respectively (Figures S9–S13); listing F-NMR spectra of compound 48 (Figure S14) (PDF)jmcmar_mfs (CSV)Compound 48-JAK1-6DBN (PDB)Compound 48-TYK2-6DBK (PDB)Compound 8-JAK1-6DBN (PDB)Compound 8-TYK2-6DBK (PDB)Compound 11-JAK1-6DBN (PDB)Compound 11-TYK2-6DBK (PDB)This article has not yet been cited by other publications.

Identification of 4-(2-furanyl)pyrimidin-2-amines As Janus Kinase 2 Inhibitors.

Design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of Janus kinase 2

Design, Synthesis and Biological Evaluation of 1-Phenanthryl-tetrahydroisoquinoline Derivatives As Novel P21-Activated Kinase 4 (PAK4) Inhibitors.

Discovery and optimization of 2-aminopyridine derivatives as novel and selective JAK2 inhibitors.

Discovery of triazolo [1,5-a] pyridine derivatives as novel JAK1/2 inhibitors.

Pharmacophore-Based Virtual Screening and Experimental Validation of Pyrazolone-Derived Inhibitors toward Janus Kinases

Discovery of furopyridine-based compounds as novel inhibitors of Janus kinase 2: In silico and in vitro studies

Structure‐guided design of potent JAK1‐selective inhibitors based on 4‐amino‐7H‐pyrrolo[2,3‐d]pyrimidine with anti‐inflammatory efficacy

Design, Synthesis and Activity Study of Pyridine Derivatives as Highly Effective and Selective TYK2 Inhibitors.

Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors.

Identification of novel inhibitors of Aurora A with a 3-(pyrrolopyridin-2-yl)indazole scaffold.

Design, synthesis and SAR study of 2-aminopyridine derivatives as potent and selective JAK2 inhibitors

Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors

N -(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms

Design, synthesis and biological evaluation of purine-based derivatives as novel JAK2/BRD4(BD2) dual target inhibitors

Discovery of Hexahydrofuro[3,2- b ]furans as New Kinase-Selective and Orally Bioavailable JAK3 Inhibitors for the Treatment of Leukemia Harboring a JAK3 Activating Mutant

Design, synthesis, and pharmacological evaluation of quinazoline derivatives as novel and potent pan-JAK inhibitors

Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors

Discovery of a Selective and Potent Inhibitor of C-Jun N-terminal Kinase 1 with Anti-Pulmonary Fibrosis Effect

Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases.

Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease